In re Terrorist Attacks on September 11, 2001, 392 F.Supp.2d 539 (2005)Analysis of One-Time Charges from the Financial Crisis Suggests Lower Net Costs for TARP and ARRA
1 duplicate copy in the archive
Cannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017)
Title Matchkaggle-ho-024690
Case Filed-30422House OversightCannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017)
November 11, 20251p
Case File
d-30422House OversightCannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017)
Other
The passage is a routine industry summary of approved cannabinoid drugs and their regulatory status. It contains no specific allegations, names of officials, financial transactions, or controversial a Lists FDA‑approved cannabinoid medicines: Marinol, Syndros, Cesamet, Sativex. Notes schedule classifications under the U.S. Controlled Substances Act. Mentions GW Pharmaceuticals as manufacturer of S
Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024690
Pages
1
Persons
0
Integrity
No Hash Available
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.